About this Tool

The Besponsa (inotuzumab ozogamicin) Dosing Calculator is designed to assist healthcare professionals in determining the appropriate, body surface area (BSA)-based dose for patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It incorporates dosing schedules for induction and subsequent cycles, accounts for patient response, and provides checks for dose modifications based on key safety parameters.

Outputs

After entering the required patient data, the calculator provides a comprehensive summary for infusion preparation and administration, including:

  • Body Surface Area (BSA): Calculated using the Du Bois formula.
  • Prescribed Dose Rate (mg/m²): The specific dose rate for the selected cycle and day.
  • Total Calculated Dose (mg): The final dose to be administered.
  • Vials Required: The number of 1 mg vials needed for reconstitution.
  • Reconstitution and Infusion Volume: Guidance on SWFI and NaCl volumes.
  • Dose Modification Alerts: Important warnings or recommendations if treatment interruption is indicated by lab values or clinical signs.
  • Premedication Reminder: A note on required premedication prior to infusion.

How to Use

To use the calculator, follow these steps:

  1. Enter Patient Measurements: Input the patient's current height and weight. Use the toggles to select the correct units (cm/in and kg/lbs).
  2. Select Treatment Phase: Choose the appropriate treatment cycle (Cycle 1 or Subsequent Cycle 2+) and the day of administration (Day 1, 8, or 15).
  3. Indicate Patient Response: For subsequent cycles (2+), specify if the patient achieved a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) after the prior cycle.
  4. Check for Dose Modifications (Optional): Select the checkbox to enter recent lab values (Total Bilirubin, AST/ALT), clinical signs of VOD/SOS, and any non-hematologic toxicity grade to check for recommended dose adjustments.
  5. Calculate: The tool automatically calculates and displays the dosing summary.

Dosing Overview

Besponsa is administered as an intravenous infusion over one hour in 3- to 4-week cycles. The dosing schedule is fractionated and depends on the treatment cycle and patient response.

Cycle 1 (Induction)

The total dose for Cycle 1 is 1.8 mg/m², administered as follows:

  • Day 1: 0.8 mg/m²
  • Day 8: 0.5 mg/m²
  • Day 15: 0.5 mg/m²

Subsequent Cycles (Consolidation)

For patients who achieve CR/CRi, the recommended dose is 1.5 mg/m² per cycle, administered as follows:

  • Day 1: 0.5 mg/m²
  • Day 8: 0.5 mg/m²
  • Day 15: 0.5 mg/m²

For patients who do not achieve CR/CRi, the dose is the same as Cycle 1 (0.8 mg/m² on Day 1, and 0.5 mg/m² on Days 8 and 15).

Premedication: Administer a corticosteroid, an antipyretic, and an antihistamine approximately 1 hour prior to each Besponsa infusion to minimize infusion-related reactions.

Switching

This section clarifies the transition from the initial induction cycle to subsequent treatment cycles. The dosing strategy changes based on the patient's hematologic response. The calculator automatically adjusts the recommended dose rate for "Subsequent Cycle (2+)" based on whether the patient achieved CR/CRi, ensuring the correct consolidation or re-induction dosing is applied.

Missed Dose

If a planned dose of Besponsa is missed, it should be administered as soon as possible. The schedule of subsequent doses should be adjusted to maintain the recommended interval between infusions. Consult the official prescribing information for detailed guidance, as the clinical team must determine the appropriate revised schedule.

Safety Alerts

The calculator includes logic to flag critical safety concerns that may require dose interruption or permanent discontinuation. Always verify with clinical assessment and the full prescribing information.

Hepatotoxicity, including VOD/SOS: Besponsa carries a boxed warning for hepatotoxicity, including veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), which can be fatal. The tool will recommend interrupting treatment if bilirubin or AST/ALT levels are significantly elevated or if clinical signs of VOD are present.
Other Non-Hematologic Toxicities: Treatment should be interrupted for any Grade ≥2 non-hematologic toxicities. The tool logic reflects that treatment may resume at the same or a reduced dose once the toxicity resolves to Grade ≤1.

FAQ

What BSA formula does the calculator use?

The calculator uses the Du Bois formula, a widely accepted method for estimating body surface area: BSA (m²) = √(Height (cm) × Weight (kg) / 3600).

Why is the dose higher on Day 1 of the first cycle?

The higher initial dose of 0.8 mg/m² serves as a loading dose during the induction phase (Cycle 1) to achieve therapeutic drug levels more rapidly. This is followed by smaller, fractionated doses to complete the cycle.

How does the calculator handle subsequent cycles if remission isn't achieved?

If a patient does not achieve CR/CRi after the first cycle, the calculator defaults to the higher-dose induction schedule (0.8 mg/m² on Day 1) for the subsequent cycle, as per the prescribing information.

What happens if I enter a high bilirubin level?

If you check for dose modifications and enter a total bilirubin level that exceeds the safety threshold (typically >2 times the upper limit of normal), the calculator will flag this and recommend interrupting treatment due to the risk of severe hepatotoxicity.

Does this tool cap the BSA at a certain value?

This educational tool calculates BSA based on the raw inputs provided. However, some institutional protocols may cap BSA at 2.0 m² or 2.2 m² for dose calculations to avoid potential toxicity in larger patients. Always adhere to local guidelines and the official prescribing information.

How is the number of vials calculated?

The number of 1 mg vials is determined by taking the total calculated dose in mg and rounding it up to the next whole number (ceiling function). This ensures enough drug is available for reconstitution.

Can I use this calculator for pediatric patients?

The safety and efficacy of Besponsa in pediatric patients have not been established. This calculator is based on adult dosing protocols. Dosing for pediatric patients must be determined by a specialist in accordance with specific clinical trial protocols or approved pediatric indications.

What are the criteria for interrupting treatment shown in the calculator?

The tool recommends interrupting treatment for: signs of VOD/SOS, significantly elevated liver enzymes (AST/ALT or bilirubin), or Grade ≥2 non-hematologic toxicities. These reflect key safety guidelines from the prescribing information.

References

This information is for educational purposes. All clinical decisions must be based on the most current version of the official prescribing information.

PRO
Ad-Free Access
$3.99 / month
  • ✓ No Interruptions
  • ✓ Faster Page Loads
  • ✓ Support Content Creators
Subscribe Now